PGAP6, a GPI-specific phospholipase A2, has narrow substrate specificity against GPI-anchored proteins

Received for publication, June 2, 2020, and in revised form, July 14, 2020. Published, Papers in Press, August 18, 2020, DOI 10.1074/jbc.RA120.014643

Gun-Hee Lee1, Morihisa Fujita2, Hideki Nakanishi2, Haruhiko Miyata1, Masahito Ikawa1,3, Yusuke Maeda1, Yoshiko Murakami1,3, and Taroh Kinoshita1,3,a

From the 1Research Institute for Microbial Diseases and the 3Immunology Frontier Research Center, Osaka University, Osaka, Japan, and the 2Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, Jiangsu, China

Edited by Dennis R. Voelker

PGAP6, also known as TMEM8A, is a phospholipase A2 with specificity to glycosylphosphatidylinositol (GPI) and expressed on the surface of various cells. CRIPTO, a GPI-anchored co-receptor for a morphogenic factor Nodal, is a sensitive substrate of PGAP6. PGAP6-mediated shedding of CRIPTO plays a critical role in an early stage of embryogenesis. In contrast, CRYP'TIC, a close family member of CRIPTO, is resistant to PGAP6. In this report, chimeras between CRIPTO and CRYP'TIC and truncate mutants of PGAP6 were used to demonstrate that the Cripto-1/FRL1/Cryptic domain of CRIPTO is recognized by an N-terminal domain of PGAP6 for processing. We also report that among 56 human GPI-anchored proteins tested, only glypican 3, prostatin, SPACA4, and contactin-1, in addition to CRIPTO, are sensitive to PGAP6, indicating that PGAP6 has a narrow specificity toward various GPI-anchored proteins.

Glycosylphosphatidylinositol (GPI)–anchored proteins (GPI-APs) are tethered to the outer leaflet of plasma membrane by a covalently linked glycolipid (1). Some GPI-APs are released from the cell surface after cleavage of the GPI anchor by GPI-specific hydrolytic enzymes (GPIases). There are several combinations of a select GPI-AP and a cognate GPIlase with particular biological significance, such as testis-specific angiogenin-converting enzyme (tACE) cleaving the GPI anchors of TEX101 and LY6K in sperm (2, 3) by its putative endomannosidase activity (4). Shedding of these GPI-APs from sperm is critical for sperm maturation (3). Several members of the glycerophosphodiesterase (GDE) family are GPI-specific phospholipase C or D (PLC or PLD). GDE2 is involved in the shedding of RECK (reversion-inducing cysteine-rich protein with Kazal motifs), a GPI-anchored protease inhibitor, from certain neuronal cells, (reversion-inducing cysteine-rich protein with Kazal motifs), a GPI-specific PLD (9). PGAP6, also known as TMEM8A, is a cell-surface phospholipase A2 (PLA2) with specificity toward GPI (9) and is widely expressed (RRID:SCR_006710) (10). PGAP6 has a large extracellular portion in the N-terminal part and seven transmembrane (TM) domains in the C-terminal part. PGAP6 belongs to a superfamily, termed CREST for alkaline ceramidase, PAQR receptor, Per1, SID-1, and TMEM8 (11). The CREST superfamily includes several lipases that have conserved, presumably catalytic amino acids within the TM domains. We reported that CRIPTO, a GPI-AP (12), is a sensitive substrate of PGAP6 (9). CRIPTO plays a role in early embryonic development by acting as a co-receptor for a morphogenic factor Nodal (13, 14). PGAP6-dependent shedding of CRIPTO is critical for its role (9), especially for the generation of the anterior–posterior axis (15).

Mechanistically, PGAP6 acts on CRIPTO in the plasma membrane and removes one fatty acyl-chain from the GPI anchor, generating CRIPTO bearing only one fatty acyl-chain. CRIPTO that is anchored to the plasma membrane by a single fatty acyl-chain is released from the membrane either spontaneously or after removal of the lipid portion by a PLD, such as GPI-specific PLD (9).

CRYP'TIC is another GPI-anchored, co-receptor for Nodal that also plays a role in early embryonic development, specifically in the generation of the left–right axis (16). CRIPTO and CRYP'TIC are similar but expressed in different regions of the embryo and basically play independent roles (16). CRIPTO and CRYP'TIC share 30% amino acid identity, have a similar domain organization, and belong to the same protein family, termed the EGF–CRIPTO–FRL1/Cryptic (CFC) family (17). In contrast to CRIPTO, CRYP'TIC is resistant to PGAP6 (9). This indicates that PGAP6 differentiates the protein part of CRIPTO from that of CRYP'TIC and selectively attacks the GPI anchor of CRIPTO but not CRYP'TIC.

In this study, we aimed to understand the basis of the protein-selective action of PGAP6. We also aimed to determine whether CRIPTO is the only substrate of PGAP6 among more than 150 human GPI-APs.

Results

CFC domain of CRIPTO determines sensitivity to PGAP6

Both CRIPTO and CRYP'TIC consist of an N-terminal signal sequence for translocation into the ER, an N-terminal (N)
domain, an EGF-like domain, a CFC domain, and a GPI-attachment signal sequence (Fig. 1) (17). To understand the basis of the different sensitivities of CRIPTO and CRYPTIC to PGAP6 and to gain insight into the substrate recognition of PGAP6, we generated chimeric proteins between CRIPTO and CRYPTIC, in which corresponding domains were swapped, and their sensitivities to PGAP6 were tested. To achieve this, the chimeric cDNAs were transfected into Chinese hamster ovary (CHO) 3B2A cells with either an empty vector or PGAP6 cDNA, and the cell-surface levels of the chimeric proteins were determined by flow cytometry (Fig. 1). If a chimera is sensitive to PGAP6, one acyl-chain will be removed from the GPI anchor, and the lipid moiety becomes lyso-PI. The resulting chimeric protein with lyso-PI form of GPI anchor has only one acyl-chain for membrane association and will be quickly released from the cell surface like lyso-phospholipids (18, 19). Therefore, the cell-surface level of the chimera will be reduced by co-transfection with PGAP6. PGAP6 sensitivity was transferred to CRYPTIC by the introduction of the CRIPTO CFC domain into CRYPTIC (chimera G; Fig. 1) B. Conversely, introduction of the CRYPTIC CFC domain into CRIPTO reduced the sensitivity of CRIPTO to PGAP6 (chimera F). Introduction of the N or the EGF-like domain of CRYPTIC into CRIPTO mildly affected sensitivity to PGAP6 (chimeras A and E). These results showed that the CFC domain confers sensitivity to PGAP6 and suggests that PGAP6 recognizes the CFC domain of CRIPTO for processing of its GPI anchor.

Site-directed CRIPTO mutants bearing amino acid substitutions in the CFC domain were generated to further analyze the basis of the CFC domain recognition by PGAP6 (Fig. 2). The CFC domains of both CRIPTO and CRYPTIC consist of 50 amino acids including six conserved cysteines that make three disulfide bonds (Fig. 2 A), suggesting that the CRIPTO and CRYPTIC CFC domains have a similar compact structure (20). Alanine mutations were introduced into residues of CRIPTO that are not conserved in CRYPTIC (red in Fig. 2 A). Mutant CRIPTO proteins with mutations in the N-terminal region of the CFC domain were expressed at normal levels (m1, m2, and m4) or at mildly reduced levels (m3 and m5) (Fig. 2) B and displayed sensitivities to PGAP6 as WT CRIPTO (Fig. 2C). Mutant

Figure 1. CFC domain of CRIPTO determines sensitivity to PGAP6. A, schematics of domain organizations of CRYPTIC, CRIPTO, and their seven domain-swapping chimeras (panels A–G). ss, signal sequence for ER localization; EGF, EGF-like domain; CFC, Cripto-1/FRL1/Cryptic domain; GPI ss, GPI attachment signal sequence. Short peptides of 6 and 10 amino acids in CRYPTIC and CRIPTO, respectively, connect CFC and GPI ss. B, cell-surface levels of CRYPTIC, CRIPTO, and their domain-swapping chimeras (panels A–G) on CHO cells with or without PGAP6 overexpression. PGAP6 sensitivity as determined by the percentage of reduction of expression levels with PGAP6 overexpression is indicated on the right. WT CRIPTO and CRYPTIC were tested under stable transfection, whereas chimeras were under transient transfection.
CRYPTOs with mutations in the C-terminal region of the CFC domain (m7–m9) had reduced expression levels (Fig. 2B) and lost sensitivities to PGAP6 (Fig. 2C). The alanine mutations that reduced expression of the mutant CRIPTO might have affected efficiency of proper disulfide bond formation within the CFC domain. These results indicate that the C-terminal region of the CFC domain is critical for recognition by PGAP6.

The N-terminal region of PGAP6 is critical for recognition of CRIPTO

We next asked what part of PGAP6 is required for its activity against CRIPTO. PGAP6 consists of the signal sequence for ER translocation, a large N-terminal domain, an EGF domain, and seven TM domains (Fig. 3A). To determine the critical region for CRIPTO recognition, several truncation mutants of PGAP6 were generated and transfected into HEK293T cells expressing HA-tagged CRIPTO. The cell-associated and the released HA-tagged CRIPTO were assessed by Western blotting (Fig. 3B), and the cell-surface levels of HA-tagged CRIPTO were examined by flow cytometry (Fig. 3C). WT PGAP6 reduced the cell-surface levels of CRIPTO by 70% and increased the CRIPTO released into the culture medium. The N domain–deleted PGAP6 (ΔN) and the N domain and the EGF domain–deleted PGAP6 (ΔNEN) lost almost all activity, whereas the EGF domain–deleted PGAP6 (ΔEGF) had mildly reduced activity (Fig. 3), indicating that the N domain of PGAP6 is critical for activity.

PGAP6/TMEM8A, TMEM8B, and TMEM8C/myomaker share a common domain organization and form the TMEM8 protein family. Amino acids with putative catalytic involvement within the second and fifth TM domains are conserved in PGAP6/TMEM8A and TMEM8B. TMEM8C/myomaker is essential for myogenesis and hence termed myomaker (21). Some of the putative catalytic amino acids are not conserved in TMEM8C/myomaker, suggesting a nonenzymatic function. We generated a chimera consisting of the N and EGF domains of PGAP6 and the seven TM domains of TMEM8B (AnBc) to test whether TMEM8B has GPI-specific PLA2 activity (Fig. 3A). AnBc had CRIPTO-releasing activity comparable with PGAP6 (Fig. 3, B and C), supporting the concept that TMEM8B may also be a GPI-specific PLA2. To determine whether the N domain plus the EGF domain of TMEM8B have CRIPTO-recognizing function, another chimera consisting of the N and EGF domains of TMEM8B and the seven TM domains of PGAP6 was generated (BnAc). BnAc was inactive in CRIPTO recognition.
GPI-specific phospholipase A2 PGAP6/TMEM8A

The full-length TMEM8B was not stably expressed after transfection into several mammalian cell lines such as HEK293 and CHO, precluding further investigation of the substrate specificity of TMEM8B (data not shown).

To demonstrate physical interaction between PGAP6 and CRIPTO in the cells by a co-immunoprecipitation assay, an enzyme-dead mutant of PGAP6, D610A, was prepared by substituting the putative catalytic aspartic acid 610 with alanine. His-FLAG–tagged D610A PGAP6 (HF-PGAP6 D610A) was co-transfected with HA-tagged CRIPTO, CRYPTIC, or CD25 into HeLaS3 cells. Co-immunoprecipitation of HF-PGAP6 D610A with HA-tagged proteins was assessed by Western blotting against a rabbit anti-PGAP6 antibody. HF-PGAP6 D610A co-immunoprecipitated with HA-tagged CRIPTO but not with HA-tagged CRYPTIC and HA-tagged CD25 (Fig. 4), demonstrating that PGAP6 and CRIPTO specifically interact with each other in cells.

**PGAP6 is not active toward a vast majority of GPI-APs, but GPC3, prostasin, SPACA4, and contactin-1 are sensitive to PGAP6**

We next asked whether PGAP6 is active against other GPI-APs because the activity of PGAP6 involves specific recognition of a region of GPI-APs by the extracellular domain and the PGAP6 extracellular domain is large. To examine the specific recognition of PGAP6, the cDNAs of 79 human GPI-APs were cloned, and an HA tag was introduced at their N termini by replacing their ER translocation signal sequences with a CD59 signal sequence fused with HA. After transfection into HEK293 cells, the cell-surface expressions of 56 of 79 were confirmed by flow cytometry using an anti-HA antibody. PGAP6 sensitivity was assessed by percentage of reduction of the cell-surface levels of HA staining by co-overexpression of PGAP6. Of the 56 GPI-APs, only four other GPI-APs: GPC3, SPACA4 (sperm acrosome-associated protein 4, also known as SAMP14) (22), prostasin, and contactin-1, were sensitive to PGAP6, showing >60% reduction (Table 1 and Fig. 5A for SPACA4). Eight GPI-APs were mildly sensitive, showing 30% to 60% reduction by PGAP6 overexpression, whereas 43 other GPI-APs were either not sensitive or only slightly sensitive (Table 1). Therefore, PGAP6 has rather narrow specificity against GPI-APs.

We then examined sperm/testis expression of mouse and human PGAP6 because SPACA4/SAMP14 is expressed only in testis and sperm. PGAP6 was detected in lysates of mouse sperm and testis and human sperm by Western blotting using a rabbit polyclonal antibody raised against human PGAP6/
TMEM8A (Fig. 5B). By immunofluorescence staining with the same antibody, PGAP6 was detected in the acrosomal cap (Fig. 5C). PGAP6 staining disappeared after the acrosomal reaction as indicated by widened IZUMO1 staining (Fig. 5C). Therefore, PGAP6 and SPACA4 are both expressed in the sperm head before the acrosomal reaction. However, whether PGAP6-dependent release of SPACA4 indeed occurs in sperm is yet to be determined. Two other sperm GPI-APs, LY6K and TEX101, which are substrates of another GPIase, tACE, were fully resistant to PGAP6 (Table 1). It was reported that SPACA4 is resistant to tACE (2, 3), further supporting that these GPIases are selective to certain GPI-APs.

Finally, the sensitivity of free, unlinked GPI to PGAP6 was examined. Some mouse tissues express free, unlinked GPI as free glycolipids (23). Cultured cell lines, defective in GPI-transamidase that attaches GPI to proteins, express high levels of free GPI on their surface (23). Transfection of PGAP6 into GPI-transamidase defective CHO cells reduced the level of free GPI by 88% as assessed by staining with the free GPI-specific T5 mAb (Fig. 6). These results suggest that PGAP6 accesses GPI when the protein part does not exist and that the protein parts of the vast majority of GPI-APs prohibit access of PGAP6 to the GPI moiety, whereas the protein parts of several GPI-APs allow PGAP6 access.

Discussion

Because of their glycolipid membrane anchors, GPI-APs can be potentially released from the cell surface by the actions of GPIases. Previously characterized GPIases are selective to only a few kinds of GPI-APs: GDE2 releases RECK and GPC6 (5,6), GDE3 releases uPAR and CNTFRα (7, 8), and tACE releases TEX101 and LY6K (2, 3). We reported previously that PGAP6 activity leads to the release of CRIPTO (9). Here, we report that PGAP6 is also active toward only a small number of GPI-APs. Among the 56 GPI-APs tested under PGAP6 overexpression conditions, only CRIPTO, GPC3, SPACA4, prostatin, and contactin-1 were highly sensitive to PGAP6. All of these previously characterized GPIase-mediated releases of select GPI-APs are the foundations of certain biological processes, such as neurogenesis, cell migration, sperm maturation and embryonic development. PGAP6-dependent release of GPC3, SPACA4, prostatin, and contactin-1 were shown only under PGAP6 overexpression conditions. Further studies are required to clarify whether the release of these proteins occurs under physiological conditions and to identify possible biological processes that are associated with the release of these proteins.

PGAP6 consists of a hydrophilic N-terminal extracellular part and a hydrophobic C-terminal part with seven TM domains. Our data showed that the extracellular part of PGAP6 attaches to proteins, express high levels of free GPI on their surface (23). Transfection of PGAP6 into GPI-transamidase defective CHO cells reduced the level of free GPI by 88% as assessed by staining with the free GPI-specific T5 mAb (Fig. 6). These results suggest that PGAP6 accesses GPI when the protein part does not exist and that the protein parts of the vast majority of GPI-APs prohibit access of PGAP6 to the GPI moiety, whereas the protein parts of several GPI-APs allow PGAP6 access.
We tested GPC1, GPC3, GPC4 and GPC5 for their sensitivities to overexpressed PGAP6. Only GPC3 was highly sensitive, whereas GPC5 was weakly sensitive, and GPC1 and GPC4 were essentially insensitive. GPC5 may not be sensitive to PGAP6 under physiological expression levels of PGAP6. GPC6 is reported to be sensitive to GDE2. Therefore, at least two GPCs, GPC3 and GPC6, are sensitive to GPI-cleaving/processing phospholipases.

Experimental procedures

Antibodies, cells, and materials

T5_4E10 mAb (T5 mAb) against free GPI-GalNAc (mouse IgM) was kindly provided by Dr. Jean François Dubremetz (Montpellier University, Montpellier, France) (25). T5_4E10 mAb is available from BEI Resources, ATCC (catalog No. NR-50267). Mouse anti-human PGAP6/TMEM8A mAb (clone 5C3, IgG2b) was a gift from Bio Legend Japan (Osaka, Japan). Polyclonal rabbit anti-PGAP6 was raised by immunization with a peptide corresponding to the C-terminal cytosolic tail of mouse PGAP6 (Scrum). Monoclonal rabbit anti-CRIPTO was from Cell Signaling Technology. Rat anti-mouse IZUMO1 mAb (clone KS64-125) was reported previously (2, 26). mAb anti-GAPDH (clone 6c5, Thermo Fisher), anti–HA tag (H7), anti-acetylated tubulin (clone 6-11B-1) (Sigma–Aldrich), and anti-tubulin and anti-transferrin receptors (Zymed Laboratories Inc., South San Francisco, CA, USA) were purchased. Secondary antibodies used were horseradish peroxidase

Table 1

| No. | GPI-AP                        | Gene name | Sensitivitya |
|-----|-------------------------------|-----------|--------------|
| 1   | CRIPTO                        | TDGF1     | High         |
| 2   | Glypican 3                    | GPC3      | High         |
| 3   | Sperm acrosome-associated protein 4 | SPACA4 | High         |
| 4   | Prostasin                     | PRSS5     | High         |
| 5   | Contactin-1                   | CNTN1     | High         |
| 6   | Lymphocyte antigen 6D         | LY6D      | Medium       |
| 7   | Ephrin A1                     | EFNA1     | Medium       |
| 8   | CD59                          | CD59      | Medium       |
| 9   | UL16-binding protein 1        | ULBP1     | Medium       |
| 10  | Dipeptidase 2                 | DPEP2     | Medium       |
| 11  | CD55                          | CD55      | Medium       |
| 12  | CAMPATH-1 antigen             | CD52      | Medium       |
| 13  | Ephrin A3                     | EFNA3     | Medium       |
| 14  | Ly6/PLAUR domain–containing protein 2 | LYPD2 | Low         |
| 15  | Lymphocyte antigen 6E         | LY6E      | Low          |
| 16  | Carboxypeptidase M            | CPM       | Low          |
| 17  | Glial cell line–derived neurotrophic factor family receptor α-1 | GFRα1 | Low          |
| 18  | Glypican 5                    | GPC5      | Low          |
| 19  | Ecto-ADP-ribosyltransferase 3 | ART3      | Low          |
| 20  | Prion protein                 | PRNP      | Resistant    |
| 21  | Opioid-binding protein/cell adhesion molecule | OPCML | Resistant    |
| 22  | Ciliary neurotrophic factor receptor subunit α | CNTFR | Resistant    |
| 23  | Reversion-inducing cysteine-rich protein with Kazal motifs | RECK | Resistant    |
| 24  | Alkaline phosphatase, non–tissue-specific isozyme | ALPL | Resistant    |
| 25  | Alkaline phosphatase, germ cell type | ALPG | Resistant    |
| 26  | Monocyte differentiation antigen CD14 | CD14 | Resistant    |
| 27  | Signal transducer CD24        | CD24      | Resistant    |
| 28  | CD48 antigen                  | CD48      | Resistant    |
| 29  | Carbonic anhydrase 4          | CA4       | Resistant    |
| 30  | Carboxypeptidase O            | CPO       | Resistant    |
| 31  | CRIPTIC                       | CFC1      | Resistant    |
| 32  | Ecto-ADP-ribosyltransferase 4 | ART4      | Resistant    |
| 33  | Ectonucleotide pyrophosphatase family member 6 | ENP6p | Resistant    |
| 34  | Folate receptor α             | FOLR1     | Resistant    |
| 35  | Glypican 1                    | GPC1      | Resistant    |
| 36  | Glypican 4                    | GPC4      | Resistant    |
| 37  | Lymphocyte antigen 6K         | LY6K      | Resistant    |
| 38  | Lymphocyte antigen 6 complex G6C | LY6G6C | Resistant    |
| 39  | Lymphocyte antigen 6 complex G6D | LY6G6D | Resistant    |
| 40  | Ly6/PLAUR domain–containing protein 1 | LYPD1 | Resistant    |
| 41  | Ly6/PLAUR domain–containing protein 6B | LYPD6B | Resistant    |
| 42  | Netrin G1                     | NTNG1     | Resistant    |
| 43  | Neural cell adhesion molecule 1 | NCAM1 | Resistant    |
| 44  | Neuronal growth regulator 1   | NEGR1     | Resistant    |
| 45  | Neurtin                       | NRRN1     | Resistant    |
| 46  | Neurtin-like protein          | NRRNL     | Resistant    |
| 47  | Oligodendrocyte-myelin glycoprotein | OMG    | Resistant    |
| 48  | Pantetheinase                 | VNN1      | Resistant    |
| 49  | Prion-like Doppel             | PRND      | Resistant    |
| 50  | Prostate stem cell antigen    | PSCA      | Resistant    |
| 51  | Testis–expressed protein 101  | TEX101    | Resistant    |
| 52  | Thy-1                         | THY1      | Resistant    |
| 53  | Tumor necrosis factor receptor superfamily 10C | TNFRSF10C | Resistant |
| 54  | UL16-binding protein 2        | ULBP2     | Resistant    |
| 55  | Urokinase plasminogen activator surface receptor | PLAUR | Resistant    |
| 56  | 5′-Nucleotidase               | NTS       | Resistant    |

aPercentage of reduction by PGAP6: high, >60%; medium, 30–60%; low, 10–30%; resistant, <10%.
(HRP)–conjugated anti-mouse IgG (GE Healthcare) and anti-rabbit IgG (Cell Signaling Technology), phycoerythrin-conjugated goat anti-mouse IgG (BD Biosciences and PharMingen, San Diego, CA), Alexa 488–conjugated goat anti-mouse IgM, Alexa 488–conjugated goat anti-mouse IgG and goat anti-rabbit IgG, and Alexa 594–conjugated goat anti-rabbit IgG (Life Technologies).

HEK293T cells stably expressing HA-tagged CRIPTO were established by transfection of linearized pME-pgkpuro-HA-CR1 and cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum and 10 μg/ml puromycin as described before (9). To prepare pME-pgkpuro-HA-CR1, we obtained human CRIPTO cDNA (Kazusa DNA Research Institute, Kisarazu, Japan) and cloned it into a mammalian expression plasmid pME bearing puromycin resistance gene and a segment of signal sequence plus HA tag. CHO cells used in this study were CHO 3B2A cells derived from CHO-K1 cells (ATCC) and stably express two human GPI-APs: CD59 and DAF (27). All CHO cell lines including WT 3B2A and 3B2A cells stably expressing HA-PGAP6, His-FLAG–tagged PGAP6, or HA-CRYPTIC (human CRYPTIC HA-tagged at the N terminus after the ER signal sequence) were cultured in Ham’s F-12 medium containing 10% fetal calf serum with 6 μg/ml basicidin, 10 μg/ml puromycin, or 500 μg/ml hygromycin, if necessary. Human CRYPTIC cDNA (clone AK315326) was obtained from NITE Biological Resource Center (Kisarazu, Japan). HeLa S3 cells (ATCC) were stably transfected with HA-CRYPTO, HA-CRYPTIC, and HA-CD25. They were then transiently transfected with an empty pME or pME bearing His-FLAG–tagged PGAP6 with D610A mutation (HF-PGAP6 D610A).

Plasmids of human GPI-APs’ cDNAs were obtained from Invitrogen. Their protein coding regions lacking the N-terminal signal sequences were cloned into pME expression vector bearing an N-terminal signal sequence of CD59 plus HA tag so that N-terminally HA-tagged GPI-APs are expressed.

**Mouse and human samples**

Mouse testis and sperm were obtained from 10-week-old B6D2F1 mice. Animal experiments were approved by the Animal Care and Use Committee of the Research Institute for Microbial Diseases, Osaka University, Japan. Human sperm were obtained from a volunteer after consent. Experiments using human samples were approved by the Ethics Committee of the Research Institute for Microbial Diseases, Osaka University, Osaka, Japan, and abide by the Declaration of Helsinki principles. Lysates of sperm and testis were prepared in a lysis buffer (6M urea, 2M thiourea, and 2% sodium deoxycholate). PGAP6 and acetylated tubulin as a loading control were detected by Western blotting against rabbit polyclonal antibody to human PGAP6 and anti-tubulin antibody. PGAP6 and IZUMO1 in mouse sperm were detected by immunofluorescence staining by rabbit polyclonal antibody to human PGAP6 (1 in 50 dilution) and rat mAb to mouse IZUMO1 (1 in 500 dilution) after incubation of sperm in TYH medium (28) for 2 h.

**Flow cytometry**

The cells were incubated with mouse T5 mAb (1 in 1,000 dilution of ascites) or anti-HA in FACS buffer (PBS containing...
1% BSA and 0.1% NaN₃ on ice for 25 min. The cells were then washed twice in FACS buffer followed by staining with Alexa Fluor 488–conjugated goat anti-mouse IgM for T5 mAb and phycoerythrin-conjugated goat anti-mouse IgG for anti-HA in FACS buffer. After washing twice with FACS buffer, the cells were analyzed by the BD FACSCanto II.

**Western blotting**

The samples were run on 10–20% gradient SDS-PAGE gels followed by transfer to polyvinylidene difluoride membranes. The polyvinylidene difluoride membranes were blocked with 5% nonfat milk in TBS/Tween 20 at room temperature for 1 h. PGAP6, HA-tagged proteins, tubulin, and GAPDH were detected using rabbit anti-PGAP6, and mouse anti-HA, anti-tubulin and anti-GAPDH (1:4000) followed by detection with HRP-conjugated anti-rabbit IgG and HRP-conjugated anti-mouse IgG (1:4000).

**Data availability**

All data from this study are contained within the article and may be shared upon request to the corresponding author.

**Acknowledgments**—We thank Dr. Jean-François Dubremetz (Montpellier University) for T5 4E10 mAb and the Edanz Group (RRID: SCR_014013) for editing a draft of this article.

**Author contributions**—G.-H. L. data curation; G.-H. L. and H. M. investigation; G.-H. L., M. F., H. N., M. I., Y. Maeda, and Y. Murakami writing-review and editing; M. F. and T. K. conceptualization; M. F. and T. K. supervision; M. F. and T. K. funding.

---

**Figure 6. Sensitivity of free, unlinked GPI to PGAP6.** WT CHO3B2A (top panel) and PIGT-defective CHO cells transfected with vector (middle panel) or PGAP6 (bottom) were stained by T5 mAb that recognizes free GPI bearing GalNAc side chain. Mean fluorescence intensity on the PGAP6-transfected cells was 11.7% of that on the vector-transfected cells.
acquisition; H. N. and M. I. resources; Y. Maeda and Y. Murakami methodology; T. K. writing-original draft; T. K. project administration.

Funding and additional information—This work was supported by Japan Society for Promotion of Science (JSPS) and Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHI Grants JP16H04753 and 17H06422 (to T. K.) and a grant for Joint Research Project of the Research Institute for Microbial Diseases, Osaka University (to M. F. and T. K.).

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: GPI, glycosylphosphatidylinositol; CFC, Cripto-1/FRL1/Cryptic; GPI-AP, GPI-anchored protein; GPIase, GPI-specific hydrolytic enzymes; tACE, testis-specific angiotensin-converting enzyme; GDE, glycerophosphodiester-tyidylinositol; CFC, Cripto-1/FRL1/Cryptic; GPI-AP, GPI-anchored protein; HR, horseradish peroxidase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

References

1. Kinoshita, T. (2020) Biosynthesis and biology of mammalian GPI-anchored proteins. Open Biol. 10, 190290 CrossRef Medline
2. Fujihara, Y., Tokuhiro, K., Muro, Y., Kondoh, G., Araki, Y., Ikawa, M., and Okabe, M. (2013) Expression of TEX101, regulated by ACE, is essential for the production of fertile mouse spermatozoa. Proc. Natl. Acad. Sci. U.S.A. 110, 8111–8116 CrossRef Medline
3. Fujihara, Y., Okabe, M., and Ikawa, M. (2014) GPI-anchored protein complex, LY6K/TEX101, is required for sperm migration into the oviduct and male fertility in mice. Biol. Reprod. 90, 60 CrossRef Medline
4. Kondoh, G., Tojo, H., Nakatani, Y., Komazawa, N., Murata, C., Yamagata, K., Maeda, Y., Kinoshita, T., Okabe, M., Taguchi, R., and Takeda, J. (2005) Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization. Nat. Med. 11, 160–166 CrossRef Medline
5. Park, S., Lee, C., Sabharwal, P., Zhang, M., Meyers, C. L., and Sockanathan, S. (2013) GDE2 promotes neurogenesis by glycosylphosphatidylinositol-anchor cleavage of RECK. Science 339, 324–328 CrossRef Medline
6. Matas-Rico, E., van Veen, M., Leyton-Puig, D., van den Berg, J., Koster, J., Kedziora, K. M., Molenaar, B., Voerts, M. J., de Rink, I., Medema, R. H., Giepmans, B. N., Perrakis, A., Jalink, K., Verstreeg, R., and Molenaar, W. H. (2016) Glycosphosphodiesterase GDE2 promotes neutrophilic differentiation through glypican release and is a marker of clinical outcome. Cancer Cell 30, 548–562 CrossRef Medline
7. van Veen, M., Matas-Rico, E., van de Wetering, K., Leyton-Puig, D., Kedziora, K. M., De Lorenzi, V., Stijf-Bultsma, Y., van den Broek, J., Jalink, K., Sidenius, N., Perrakis, A., and Molenaar, W. H. (2017) Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells. Life 6, e23649 CrossRef Medline
8. Dobrowolski, M., Cave, C., Levy-Myers, R., Lee, C., Park, S., Choi, B. R., Xiao, B., Yang, W., and Sockanathan, S. (2020) GDE3 regulates oligodendrocyte precursor proliferation via release of soluble CNTFRα. Development 147, dev180695 CrossRef Medline
9. Lee, G. H., Fujita, M., Takaoka, K., Murakami, Y., Fujihira, Y., Kanzawa, N., Murakami, K. I., Kajikawa, E., Takada, Y., Saito, K., Ikawa, M., Hamada, H., Maeda, Y., and Kinoshita, T. (2016) A GPI processing phospholipase A2, PGAPA6, modulates Nodal signaling in embryos by shedding CRIPTO. J. Cell Biol. 215, 705–718 CrossRef Medline
10. Fagerberg, L., Hallström, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habak, M., Tahmasebpour, S., Danielsson, A., Edlund, K., Asplund, A., Jöststedt, E., Lundberg, E., Szigyarto, C. A., Skogs, M., et al. (2014) Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell. Proteomics 13, 397–406 CrossRef Medline
11. Pei, J., Millay, D. P., Olson, E. N., and Grishin, N. V. (2011) CREST: a large and diverse superfamily of putative transmembrane hydrolases. Biol. Direct 6, 37 CrossRef Medline
12. Minchiotti, G., Parisi, S., Liguori, G., Signore, M., Lania, G., Adamson, E. D., Lago, C. T., and Persico, M. G. (2000) Membrane-anchorage of Cripto protein by glycosphosphatidylinositol and its distribution during early mouse development. Mech. Dev. 90, 133–142 CrossRef Medline
13. Tian, T., and Meng, A. M. (2006) Nodal signals pattern vertebrate embryos. Cell. Mol. Life Sci. 63, 672–685 CrossRef Medline
14. Shen, M. M. (2007) Nodal signaling: developmental roles and regulation. Development 134, 1023–1034 CrossRef Medline
15. Ding, J., Yang, L., Yan, Y. T., Chen, A., Desai, N., Wynshaw-Boris, A., and Shen, M. M. (1998) Cripto is required for correct orientation of the anterior–posterior axis in the mouse embryo. Nature 395, 702–707 CrossRef Medline
16. Chu, J., and Shen, M. M. (2010) Functional redundancy of EGF-CFC genes in epiblast and extraembryonic patterning during early mouse embryogenesis. Dev. Biol. 342, 63–73 CrossRef Medline
17. Shen, M. M., and Schier, A. F. (2000) The EGF-CFC gene family in vertebrate development. Trends Genet. 16, 303–309 CrossRef Medline
18. Holthuis, J. C., and Levine, T. P. (2005) Lipid traffic: floppy drives and a superhighway. Nat. Rev. Mol. Cell Biol. 6, 209–220 CrossRef Medline
19. Lev, S. (2010) Non-vesicular lipid transport by lipid-transfer proteins and beyond. Nat. Rev. Mol. Cell Biol. 11, 739–750 CrossRef Medline
20. Foley, S. F., van Vlijmen, H. W., Boynton, R. E., Adkins, H. B., Cheung, A. E., Singh, J., Sanicola, M., Young, C. N., and Wen, D. (2003) The CRIPTO/FRL1/CRYPTIC (CFC) domain of human Cripto: functional and structural insights through disulfide structure analysis. Eur. J. Biochem. 270, 3610–3618 CrossRef Medline
21. Millay, D. P., O’Rourke, J. R., Sutherland, L. B., Bezprozvannaya, S., Shilton, J. M., Bassel-Duby, R., and Olson, E. N. (2013) Myomaker is a membrane activator of myoblast fusion and muscle formation. Nature 499, 301–305 CrossRef Medline
22. Shetty, J., Wolkowicz, M. J., Digilio, L. C., Klotz, K. L., Jayes, F. L., Diekmann, A. B., Westbrook, V. A., Farris, E. M., Hao, Z., Coomrod, S. A., Flickinger, C. J., and Herr, J. C. (2003) SAMP14, a novel, acrosomal membrane-associated, glycosphosphatidylinositol-anchored member of the Ly-6/urokinase-type plasminogen activator receptor superfamily with a role in sperm–egg interaction. J. Biol. Chem. 278, 30506–30515 CrossRef Medline
23. Yamasaki, H., Hirata, T., Maeda, Y., Murakami, Y., Fujita, M., and Kinoshita, T. (2019) Free, unlinked glycosphosphatidylinositols on mammalian cell surfaces revisited. J. Biol. Chem. 294, 5038–5049 CrossRef Medline
24. Maeda, Y., Tashima, Y., Houjou, T., Fujita, M., Yoko-O, T., Jigami, Y., Taguchi, R., and Kinoshita, T. (2007) Fatty acid remodeling of GPI-anchored proteins are required for their raft association. Mol. Biol. Cell 18, 1497–1506 CrossRef Medline
25. Tomavo, S., Couvreur, G., Leriche, M. A., Sadak, A., Achbarou, A., Fortier, B., and Dubremetz, J. F. (1994) Immunolocalization and characterization of the low molecular weight antigen (4–5 kDa) of Toxoplasma gondii that elicits an early IgM response upon primary infection. Parasitology 108, 139–145 CrossRef Medline
26. Ikawa, M.,Tokuhirio, K., Yamaguchi, R., Benham, A. M., Tamura, T., Wada, I., Satou, Y., Ionue, N., and Okabe, M. (2011) Calsperrin is a testis-specific chaperone required for sperm fertility. J. Biol. Chem. 286, 5639–5646 CrossRef Medline
27. Nakamura, N., Ionue, N., Watanabe, R., Takahashi, M., Takeda, J., Stevens, V. L., and Kinoshita, T. (1997) Expression cloning of PIG-L, a candidate N-acetylgalactosaminyl-phosphatidylinositol deacylase. J. Biol. Chem. 272, 15834–15840 CrossRef Medline
28. Muro, Y., Hasuwa, H., Isotani, A., Miyata, H., Yamagata, K., Ikawa, M., Yanagimachi, R., and Okabe, M. (2016) Behavior of mouse spermatozoa in the female reproductive tract from soon after mating to the beginning of fertilization. Biol. Reprod. 94, 80 CrossRef Medline